Risk Factors for Invasive Fungal Infection in Lung Transplant Recipients on Universal Antifungal Prophylaxis
Open Forum Infectious Diseases · 01.02.2024 · 11 (2)
DOI: 10.1093/ofid/ofad640 ↗Kurz gefasst
Fachartikel in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 19.12.2023. Verfasst von Jonathan P Huggins und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCATS NIH HHS, National Center for Advancing Translational Sciences, National Institutes of Health.
Abstract (Originalsprache)
Background
Many centers use universal antifungal prophylaxis after lung transplant, but risk factors for invasive fungal infection (IFI) in this setting are poorly described. Methods This retrospective, single-center cohort study including 603 lung transplant recipients assessed risk factors for early (within 90 days of transplant) invasive candidiasis (IC) and invasive mold infection (IMI) and late (90–365 days after transplant) IMI using Cox proportional hazard regression.
Results
In this cohort, 159 (26.4%) patients had 182 IFIs. Growth of yeast on donor culture (hazard ratio [HR], 3.30; 95% CI, 1.89–5.75) and prolonged length of stay (HR, 1.02; 95% CI, 1.01–1.03) were associated with early IC risk, whereas transplantation in 2016 or 2017 (HR, 0.21; 95% CI, 0.06–0.70; HR, 0.25; 95% CI, 0.08–0.80, respectively) and female recipient sex (HR, 0.53; 95% CI, 0.30–0.93) were associated with reduced risk. Antimold therapy (HR, 0.21; 95% CI, 0.06–0.78) was associated with lower early IMI risk, and female donor sex (HR, 0.40; 95% CI, 0.22–0.72) was associated with lower late IMI risk. Recent rejection was a risk factor for late IMI (HR, 1.73; 95% CI, 1.02–2.95), and renal replacement therapy predisposed to early IC, early IMI, and late IMI (HR, 5.67; 95% CI, 3.01–10.67; HR, 7.54; 95% CI, 1.93–29.45; HR, 5.33; 95% CI, 1.46–19.49, respectively).
Conclusions
In lung transplant recipients receiving universal antifungal prophylaxis, risk factors for early IC, early IMI, and late IMI differ.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.
- School of Medicine, Duke University, Durham, North Carolina, USA.
- Department of Biostatistics & Bioinformatics, Duke University, Durham, North Carolina, USA.
- Sentara Healthcare, Norfolk, Virginia, USA.
ORCID-Profile: Jonathan P Huggins
Förderung
- NCATS NIH HHS
- National Center for Advancing Translational Sciences
- National Institutes of Health
Zitieren
APA
Huggins, J. P., Arthur, D., Chow, S. C., Pease, R., Stanly, K., Workman, A., Reynolds, J., & Alexander, B. D. (2024). Risk Factors for Invasive Fungal Infection in Lung Transplant Recipients on Universal Antifungal Prophylaxis. Open Forum Infectious Diseases, 11(2). https://doi.org/10.1093/ofid/ofad640
Vancouver
Huggins JP, Arthur D, Chow SC, Pease R, Stanly K, Workman A, et al. Risk Factors for Invasive Fungal Infection in Lung Transplant Recipients on Universal Antifungal Prophylaxis. Open Forum Infectious Diseases. 2024;11(2). doi:10.1093/ofid/ofad640
BibTeX
@article{Huggins2024,
author = {Huggins, Jonathan P and Arthur, David and Chow, Shein-Chung and Pease, Robert and Stanly, Kelly and Workman, Adrienne and Reynolds, John and Alexander, Barbara D},
title = {Risk Factors for Invasive Fungal Infection in Lung Transplant Recipients on Universal Antifungal Prophylaxis},
journal = {Open Forum Infectious Diseases},
year = {2024},
volume = {11},
number = {2},
doi = {10.1093/ofid/ofad640}
}
EUVIMED